Vigil Neuroscience to Present at Upcoming September Investor Conferences
Vigil Neuroscience (Nasdaq: VIGL), a clinical-stage biotech company focusing on microglia-based treatments for neurodegenerative diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat scheduled for Thursday, September 5th at 2:35 p.m. ET.
2. H.C. Wainwright 26th Annual Global Investment Conference: Another fireside chat set for Tuesday, September 10th at 10:30 a.m. ET.
Both events will feature live webcasts available on the company's website under the 'Events & Presentations' page in the 'Investors' section. These webcasts will remain accessible for approximately 90 days after the presentations.
Vigil Neuroscience (Nasdaq: VIGL), una azienda biotech in fase clinica focalizzata su trattamenti a base di microglia per le malattie neurodegenerative, ha annunciato la sua partecipazione a due prossimi conferenze per investitori a settembre 2024:
1. Conferenza Sanitaria Globale Annuale di Morgan Stanley: Un colloquio informale programmato per giovedì 5 settembre alle 14:35 ET.
2. Conferenza Globale Annuale di Investimento H.C. Wainwright: Un altro colloquio informale fissato per martedì 10 settembre alle 10:30 ET.
Entrambi gli eventi presenteranno webcast dal vivo disponibili sul sito web dell'azienda nella pagina 'Eventi e Presentazioni' nella sezione 'Investitori'. Questi webcast saranno accessibili per circa 90 giorni dopo le presentazioni.
Vigil Neuroscience (Nasdaq: VIGL), una empresa biotécnica en etapa clínica centrada en tratamientos basados en microglía para enfermedades neurodegenerativas, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024:
1. 22ª Conferencia Anual Global de Salud de Morgan Stanley: Una charla informal programada para el jueves 5 de septiembre a las 2:35 p.m. ET.
2. 26ª Conferencia Anual Global de Inversión de H.C. Wainwright: Otra charla informal establecida para el martes 10 de septiembre a las 10:30 a.m. ET.
Ambos eventos contarán con webcasts en vivo disponibles en el sitio web de la empresa en la página 'Eventos y Presentaciones' en la sección 'Inversores'. Estos webcasts estarán accesibles durante aproximadamente 90 días después de las presentaciones.
비질 신경과학 (Nasdaq: VIGL)은 신경퇴행성 질환에 대한 미세아교세포 기반 치료법에 집중하는 임상 단계의 생명공학 회사로, 2024년 9월에 예정된 두 개의 투자자 회의에 참여한다고 발표했습니다:
1. 모건스탠리 제22회 연례 글로벌 헬스케어 회의: 9월 5일 목요일 오후 2시 35분 ET에 예정된 화재 측면 대화입니다.
2. H.C. 웨인라이트 제26회 연례 글로벌 투자 회의: 9월 10일 화요일 오전 10시 30분 ET에 예정된 또 다른 화재 측면 대화입니다.
두 이벤트 모두 실시간 웹캐스트가 진행되며, 이는 회사 웹사이트의 '이벤트 및 발표' 페이지에서 '투자자' 섹션 하에 제공됩니다. 이 웹캐스트는 발표 후 약 90일 동안 접근할 수 있습니다.
Vigil Neuroscience (Nasdaq: VIGL), une entreprise biopharmaceutique en phase clinique axée sur les traitements basés sur les microglies pour les maladies neurodégénératives, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024 :
1. 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley : Une discussion informelle prévue pour le jeudi 5 septembre à 14h35 ET.
2. 26ème Conférence Annuelle Mondiale d'Investissement de H.C. Wainwright : Une autre discussion informelle prévue pour le mardi 10 septembre à 10h30 ET.
Les deux événements présenteront des webcasts en direct disponibles sur le site web de l'entreprise dans la page 'Événements et Présentations' de la section 'Investisseurs'. Ces webcasts resteront accessibles pendant environ 90 jours après les présentations.
Vigil Neuroscience (Nasdaq: VIGL), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mikroglia-basierte Behandlungen für neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 bekannt gegeben:
1. 22. Jährliche Globale Gesundheitskonferenz von Morgan Stanley: Ein lockeres Gespräch, das für Donnerstag, den 5. September, um 14:35 Uhr ET angesetzt ist.
2. 26. Jährliche Globale Investitionskonferenz von H.C. Wainwright: Ein weiteres lockeres Gespräch, das für Dienstag, den 10. September, um 10:30 Uhr ET festgelegt ist.
Beide Veranstaltungen werden live-Webcasts anbieten, die auf der Website des Unternehmens unter der Seite 'Veranstaltungen & Präsentationen' im Bereich 'Investoren' verfügbar sind. Diese Webcasts werden etwa 90 Tage nach den Präsentationen zugänglich sein.
- None.
- None.
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
Morgan Stanley 22nd Annual Global Healthcare Conference
Format: Fireside Chat
Date/Time: Thursday, September 5th at 2:35 p.m. ET
H.C. Wainwright 26th Annual Global Investment Conference
Format: Fireside Chat
Date/Time: Tuesday, September 10th at 10:30 a.m. ET
The live webcasts from the events will be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. Archived webcasts will be available for approximately 90 days following the presentation.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.
Internet Posting of Information
Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.
Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com
Media Contact:
Megan McGrath
CTD Comms, LLC
megan@ctdcomms.com
FAQ
When is Vigil Neuroscience (VIGL) presenting at the Morgan Stanley Global Healthcare Conference in September 2024?
What type of presentation will Vigil Neuroscience (VIGL) give at the H.C. Wainwright Global Investment Conference in September 2024?
How can investors access Vigil Neuroscience's (VIGL) presentations at the September 2024 conferences?
What is the focus of Vigil Neuroscience's (VIGL) research and development?
